Business
Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors
CAMBRIDGE, Mass., August 12, 2025--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic payloads to solid tumors, today announced the appointment of Andrew Hirsch, MBA, to the Company’s Board of Directors.
About this update from C4 Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1350,"height":450,"url":"https://media.zenfs.com/en/business-wire.com/57ef6502b69934bc9088cb596a9d9a7f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FoiBPD_.8WldLc4MWqPuzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/57ef6502b69934bc9088cb596a9d9a7f","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/1nc3764bkbEQNUcwa4F0Fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/57ef6502b69934bc9088cb596a9d9a7f","width":1200,"height":400}},"lazy":false},{"type":"text","content":"President and CEO of C4 Therapeutics brings decades of experience spanning finance, operations, and innovative life science company-building","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., August 12, 2025--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic payloads to solid tumors, today announced the appointment of Andrew Hirsch, MBA, to the Company’s Board of Directors.","length":324,"tagName":"p"},{"type":"text","content":""We are delighted to welcome Andrew Hirsch to our Board of Directors," said Howard Davis, PhD, Chief Executive Officer of Akamis Bio. "His extensive industry leadership, operational and strategic expertise, and proven ability to advance novel therapeutic modalities make him an exceptional addition to our Board. Andrew’s insights will be instrumental as we unlock the full potential of our immunotherapeutic platform across a range of oncology indications, starting with our lead clinical program for locally advanced rectal cancer."","length":554,"tagName":"p"},{"type":"text","content":"Since 2020, Mr. Hirsch has been President, CEO and a member of the Board of Directors of C4 Therapeutics, a clinical-stage company advancing a pipeline of targeted protein degraders for a number of indications including oncology. He was previously Chief Financial Officer and Head of Corporate Development at Agios Pharmaceuticals, President and CEO of BIND Therapeutics, Chief Financial Officer at Avila Therapeutics, and Vice...